Literature DB >> 34023508

Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy.

Yohei Kawai1, Ai Kawana-Tachikawa2, Shuichi Kitayama1, Tatsuki Ueda1, Shoji Miki2, Akira Watanabe3, Shin Kaneko4.   

Abstract

Adoptive immunotherapy has emerged as a powerful approach to cure cancer and chronic infections. Currently, the generation of a massive number of T cells that provide long-lasting immunity is challenged by exhaustion and differentiation-associated senescence, which inevitably arise during in vitro cloning and expansion. To circumvent these problems, several studies have proposed an induced pluripotent stem cell (iPSC)-mediated rejuvenation strategy to revitalize the exhausted/senescent T cell clones. Because iPSC-derived cytotoxic T lymphocytes (iPSC-CTLs) generated via commonly used monolayer systems have unfavorable, innate-like features such as aberrant natural killer (NK) activity and limited replication potential, we modified the redifferentiation culture to generate CD8αβ+CD5+CCR7+CD45RA+CD56--adaptive iPSC-CTLs. The modified iPSC-CTLs exhibited early memory phenotype, including high replicative capacity and the ability to give rise to potent effector cells. In expansion culture with an optimized cytokine cocktail, iPSC-CTLs proliferated more than 1015-fold in a feeder-free condition. Our redifferentiation and expansion package of early memory iPSC-CTLs could supply memory and effector T cells for both autologous and allogeneic immunotherapies.
Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  T cell differentiation; iPS cell; rejuvenated T cell; stemness

Mesh:

Substances:

Year:  2021        PMID: 34023508      PMCID: PMC8530944          DOI: 10.1016/j.ymthe.2021.05.016

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   12.910


  76 in total

1.  A novel transcription factor, T-bet, directs Th1 lineage commitment.

Authors:  S J Szabo; S T Kim; G L Costa; X Zhang; C G Fathman; L H Glimcher
Journal:  Cell       Date:  2000-03-17       Impact factor: 41.582

Review 2.  Tumor immunology: the first century.

Authors:  L J Old
Journal:  Curr Opin Immunol       Date:  1992-10       Impact factor: 7.486

3.  TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells.

Authors:  Konstantinos A Papadakis; John L Prehn; Carol Landers; Qiwei Han; Xia Luo; Stephanie C Cha; Ping Wei; Stephan R Targan
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

4.  ITK and IL-15 support two distinct subsets of CD8+ T cells.

Authors:  Sigrid Dubois; Thomas A Waldmann; Jürgen R Müller
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

5.  TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.

Authors:  Thi Sau Migone; Jun Zhang; Xia Luo; Li Zhuang; Cecil Chen; Bugen Hu; June S Hong; James W Perry; Su Fang Chen; Joe X H Zhou; Yun Hee Cho; Stephen Ullrich; Palanisamy Kanakaraj; Jeffrey Carrell; Ernest Boyd; Henrik S Olsen; Gang Hu; Laurie Pukac; Ding Liu; Jian Ni; Sunghee Kim; Reiner Gentz; Ping Feng; Paul A Moore; Steve M Ruben; Ping Wei
Journal:  Immunity       Date:  2002-03       Impact factor: 31.745

6.  Regeneration of CD8αβ T Cells from T-cell-Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity.

Authors:  Takuya Maeda; Seiji Nagano; Hiroshi Ichise; Keisuke Kataoka; Daisuke Yamada; Seishi Ogawa; Haruhiko Koseki; Toshio Kitawaki; Norimitsu Kadowaki; Akifumi Takaori-Kondo; Kyoko Masuda; Hiroshi Kawamoto
Journal:  Cancer Res       Date:  2016-11-21       Impact factor: 12.701

Review 7.  Advances in IL-21 biology - enhancing our understanding of human disease.

Authors:  Stuart G Tangye
Journal:  Curr Opin Immunol       Date:  2015-03-23       Impact factor: 7.486

8.  A human memory T cell subset with stem cell-like properties.

Authors:  Luca Gattinoni; Enrico Lugli; Yun Ji; Zoltan Pos; Chrystal M Paulos; Máire F Quigley; Jorge R Almeida; Emma Gostick; Zhiya Yu; Carmine Carpenito; Ena Wang; Daniel C Douek; David A Price; Carl H June; Francesco M Marincola; Mario Roederer; Nicholas P Restifo
Journal:  Nat Med       Date:  2011-09-18       Impact factor: 53.440

9.  Downregulation of CD1 marks acquisition of functional maturation of human thymocytes and defines a control point in late stages of human T cell development.

Authors:  P Res; B Blom; T Hori; K Weijer; H Spits
Journal:  J Exp Med       Date:  1997-01-06       Impact factor: 14.307

10.  Reprogramming human T cell function and specificity with non-viral genome targeting.

Authors:  Theodore L Roth; Cristina Puig-Saus; Ruby Yu; Eric Shifrut; Julia Carnevale; P Jonathan Li; Joseph Hiatt; Justin Saco; Paige Krystofinski; Han Li; Victoria Tobin; David N Nguyen; Michael R Lee; Amy L Putnam; Andrea L Ferris; Jeff W Chen; Jean-Nicolas Schickel; Laurence Pellerin; David Carmody; Gorka Alkorta-Aranburu; Daniela Del Gaudio; Hiroyuki Matsumoto; Montse Morell; Ying Mao; Min Cho; Rolen M Quadros; Channabasavaiah B Gurumurthy; Baz Smith; Michael Haugwitz; Stephen H Hughes; Jonathan S Weissman; Kathrin Schumann; Jonathan H Esensten; Andrew P May; Alan Ashworth; Gary M Kupfer; Siri Atma W Greeley; Rosa Bacchetta; Eric Meffre; Maria Grazia Roncarolo; Neil Romberg; Kevan C Herold; Antoni Ribas; Manuel D Leonetti; Alexander Marson
Journal:  Nature       Date:  2018-07-11       Impact factor: 49.962

View more
  4 in total

1.  Sustainable Antiviral Efficacy of Rejuvenated HIV-Specific Cytotoxic T Lymphocytes Generated from Induced Pluripotent Stem Cells.

Authors:  Shoji Miki; Yohei Kawai; Kaori Nakayama-Hosoya; Ryutaro Iwabuchi; Kazutaka Terahara; Yasuko Tsunetsugu-Yokota; Michiko Koga; Tetsuro Matano; Shin Kaneko; Ai Kawana-Tachikawa
Journal:  J Virol       Date:  2022-02-02       Impact factor: 6.549

Review 2.  Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies.

Authors:  Roberta Mazza; John Maher
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-12-12       Impact factor: 4.291

Review 3.  Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells.

Authors:  Ratchapong Netsrithong; Methichit Wattanapanitch
Journal:  Front Immunol       Date:  2021-09-28       Impact factor: 7.561

Review 4.  Current Status and Prospects of Clinical Treatment of Osteosarcoma.

Authors:  Zong-Yuan Jiang; Ji-Bin Liu; Xiao-Feng Wang; Yu-Shui Ma; Da Fu
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.